At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Post-Mkt 04-30 17:42:10 EDT
8.98
-0.07
-0.77%
盘后8.98
+0.000.00%
16:10 EDT
High9.40Low8.93Vol843.94K
Open9.05D1 Closing9.05Amplitude5.14%
Mkt Cap280.98MTradable Cap140.92MTotal Shares31.29M
T/O7.72MT/O Rate5.38%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
Dow Jones  ·  26 minutes ago
Press Release: Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update
Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)
TIPRANKS  ·  50 minutes ago
Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)
Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate
Benzinga  ·  54 minutes ago
Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
GlobeNewswire  ·  04:05
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
GlobeNewswire  ·  04:05
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies
TIPRANKS  ·  03:56
Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
GlobeNewswire  ·  03:00
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
Hemab Therapeutics 15M share IPO price range $16.00-$18.00
TIPRANKS  ·  02:57
Hemab Therapeutics 15M share IPO price range $16.00-$18.00
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
TIPRANKS  ·  04-30 21:59
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
Pliant Therapeutics doses first participant in FORTIFY expansion trial
TIPRANKS  ·  04-30 21:41
Pliant Therapeutics doses first participant in FORTIFY expansion trial
Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million
Dow Jones  ·  04-30 21:34
Hemab Therapeutics Boosts IPO to 15 Million Shares from 11.8 Million
Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c)
TIPRANKS  ·  04-30 21:11
Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c)
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
GlobeNewswire  ·  04-30 21:00
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Press Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
Dow Jones  ·  04-30 20:32
Press Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
GlobeNewswire  ·  04-30 20:30
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire  ·  04-30 20:30
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Press Release: Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board
Dow Jones  ·  04-30 20:12
Press Release: Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
GlobeNewswire  ·  04-30 20:05
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate
Benzinga  ·  04-30 19:25
Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
GlobeNewswire  ·  04-30 19:25
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--